|
1
|
American Cancer Society: Cancer Facts
& Figures, . American Cancer Society. http://www.cancer.org/acs/groups/content/@research/documents/document/acspc-047079.pdfMarch
21–2016
|
|
2
|
Oza AM, Cook AD, Pfisterer J, Embleton A,
Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P,
Cervantes A, et al: Standard chemotherapy with or without
bevacizumab for women with newly diagnosed ovarian cancer (ICON7):
overall survival results of a phase 3 randomised trial. Lancet
Oncol. 16:928–936. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Aghajanian C, Goff B, Nycum LR, Wang YV,
Husain A and Blank SV: Final overall survival and safety analysis
of OCEANS, a phase 3 trial of chemotherapy with or without
bevacizumab in patients with platinum-sensitive recurrent ovarian
cancer. Gynecol Oncol. 139:10–16. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Perren TJ, Swart AM, Pfisterer J,
Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P,
Cervantes A, Kurzeder C, et al: A phase 3 trial of bevacizumab in
ovarian cancer. N Engl J Med. 365:2484–2496. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Aghajanian C, Blank SV, Goff BA, Judson
PL, Teneriello MG, Husain A, Sovak MA, Yi J and Nycum LR: OCEANS: A
randomized, double-blind, placebo-controlled phase III trial of
chemotherapy with or without bevacizumab in patients with
platinum-sensitive recurrent epithelial ovarian, primary
peritoneal, or fallopian tube cancer. J Clin Oncol. 30:2039–2045.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Stockler MR, Hilpert F, Friedlander M,
King MT, Wenzel L, Lee CK, Joly F, de Gregorio N, Arranz JA, Mirza
MR, et al: Patient-reported outcome results from the open-label
phase III AURELIA trial evaluating bevacizumab-containing therapy
for platinum-resistant ovarian cancer. J Clin Oncol. 32:1309–1316.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Oza AM, Cibula D, Benzaquen AO, Poole C,
Mathijssen RH, Sonke GS, Colombo N, Špaček J, Vuylsteke P, Hirte H,
et al: Olaparib combined with chemotherapy for recurrent
platinum-sensitive ovarian cancer: A randomised phase 2 trial.
Lancet Oncol. 16:87–97. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Liu JF, Barry WT, Birrer M, Lee JM,
Buckanovich RJ, Fleming GF, Rimel B, Buss MK, Nattam S, Hurteau J,
et al: Combination cediranib and olaparib versus olaparib alone for
women with recurrent platinum-sensitive ovarian cancer: A
randomised phase 2 study. Lancet Oncol. 15:1207–1214. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gillies RJ, Raghunand N, Karczmar GS and
Bhujwalla ZM: MRI of the tumor microenvironment. J Magn Reson
Imaging. 16:430–450. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Loo SY, Chang MK, Chua CS, Kumar AP,
Pervaiz S and Clement MV: NHE-1: A promising target for novel
anti-cancer therapeutics. Curr Pharm Des. 18:1372–1382. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Amith SR and Fliegel L: Regulation of the
Na+/H+ exchanger (NHE1) in breast cancer metastasis. Cancer Res.
73:1259–1264. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Amith SR, Wilkinson JM, Baksh S and
Fliegel L: The Na+/H+ exchanger (NHE1) as a
novel co-adjuvant target in paclitaxel therapy of triple-negative
breast cancer cells. Oncotarget. 6:1262–1275. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lin Y, Chang G, Wang J, Jin W, Wang L, Li
H, Ma L, Li Q and Pang T: NHE1 mediates MDA-MB-231 cells invasion
through the regulation of MT1-MMP. Exp Cell Res. 317:2031–2040.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yang X, Wang D, Dong W, Song Z and Dou K:
Suppression of Na+/H+ exchanger 1 by RNA interference or amiloride
inhibits human hepatoma cell line SMMC-7721 cell invasion. Med
Oncol. 28:385–390. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yang X, Wang D, Dong W, Song Z and Dou K:
Expression and modulation of Na(+) /H(+) exchanger 1 gene in
hepatocellular carcinoma: A potential therapeutic target. J
Gastroenterol Hepato. 26:364–370. 2011. View Article : Google Scholar
|
|
16
|
Cardone RA, Greco MR, Zeeberg K,
Zaccagnino A, Saccomano M, Bellizzi A, Bruns P, Menga M, Pilarsky
C, Schwab A, et al: A novel NHE1-centered signaling cassette drives
epidermal growth factor receptor–dependent pancreatic tumor
metastasis and is a target for combination therapy. Neoplasia.
17:155–166. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lin Y, Wang J, Jin W, Wang L, Li H, Ma L,
Li Q and Pang T: NHE1 mediates migration and invasion of HeLa cells
via regulating the expression and localization of MT1-MMP. Cell
Biochem Funct. 30:41–46. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
18
|
Jin W, Li Q, Wang J, Chang G, Lin Y, Li H,
Wang L, Gao W and Pang T: Na+/H+ exchanger 1 inhibition contributes
to K562 leukaemic cell differentiation. Cell Biol Int. 36:739–745.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Tang L, Yang J, Ng SK, Rodriguez N, Choi
PW, Vitonis A, Wang K, McLachlan GJ, Caiazzo RJ Jr, Liu BC, et al:
Autoantibody profiling to identify biomarkers of key pathogenic
pathways in mucinous ovarian cancer. Eur J Cancer. 46:170–179.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wang H, Mu X, Zhou S, Zhang J, Dai J, Tang
L, Xiao L, Duan Z, Jia L and Chen S: NEDD9 overexpression is
associated with the progression of and an unfavorable prognosis in
epithelial ovarian cancer. Hum Pathol. 45:401–408. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Greco MR, Antelmi E, Busco G, Guerra L,
Rubino R, Casavola V, Reshkin SJ and Cardone RA: Protease activity
at invadopodial focal digestive areas is dependent on NHE1-driven
acidic pHe. Oncol Rep. 31:940–946. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Maly K, Strese K, Kampfer S, Ueberall F,
Baier G, Ghaffari-Tabrizi N, Grunicke HH and Leitges M: Critical
role of protein kinase C alpha and calcium in growth factor induced
activation of the Na+/H+ exchanger NHE1. FEBS Lett. 521:205–210.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Cardone RA, Casavola V and Reshkin SJ: The
role of disturbed pH dynamics and the Na+/H+ exchanger in
metastasis. Nat Rev Cancer. 5:786–795. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Stock C, Ludwig FT and Schwab A: Is the
multifunctional Na(+)/H(+) exchanger isoform 1 a potential
therapeutic target in cancer? Curr Med Chem. 19:647–660. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Cong D, Zhu W, Shi Y, Pointer KB, Clark
PA, Shen H, Kuo JS, Hu S and Sun D: Upregulation of NHE1 protein
expression enables glioblastoma cells to escape TMZ-mediated
toxicity via increased H+ extrusion, cell migration and
survival. Carcinogenesis. 35:2014–2024. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhu W, Carney KE, Pigott VM, Falgoust LM,
Clark PA, Kuo JS and Sun D: Glioma-mediated microglial activation
promotes glioma proliferation and migration: Roles of Na+/H+
exchanger isoform 1. Carcinogenesis. 37:839–851. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Paradiso A, Cardone RA, Bellizzi A,
Bagorda A, Guerra L, Tommasino M, Casavola V and Reshkin SJ: The
Na+-H+ exchanger-1 induces cytoskeletal
changes involving reciprocal RhoA and Rac1 signaling, resulting in
motility and invasion in MDA-MB-435 cells. Breast Cancer Res.
6:R616–R628. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
29
|
Reshkin SJ, Bellizzi A, Cardone RA,
Tommasino M, Casavola V and Paradiso A: Paclitaxel induces
apoptosis via protein kinase A- and p38 mitogen-activated
protein-dependent inhibition of the Na+/H+ exchanger (NHE) NHE
isoform 1 in human breast cancer cells. Clin Cancer Res.
9:2366–2373. 2003.PubMed/NCBI
|
|
30
|
Ariyoshi Y, Shiozaki A, Ichikawa D,
Shimizu H, Kosuga T, Konishi H, Komatsu S, Fujiwara H, Okamoto K,
Kishimoto M, et al: Na+/H+ exchanger 1 has tumor suppressive
activity and prognostic value in esophageal squamous cell
carcinoma. Oncotarget. 8:2209–2223. 2017. View Article : Google Scholar : PubMed/NCBI
|
